

Company Overview


T-NanoBio Therapeutics, Inc., a Delaware corporation, is an emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Our nano immuno-engager (“NIE”) platform can harness a patient’s own immune system against cancer. In addition, the Company will work with the premier institution assessing the tumor microenvironment coupled with machine learning (AI) to predict responders. The company has sufficient data to progress into pharma/tox studies within 6 months of funding, followed by an IND filing within 9 months. The Company is comprised of a very senior and seasoned team with expertise in science, clinical development, finance, business, commercialization, CMC and corporate development with over 120 years of combined experience.

Platform Highlights

- Demonstrated conversion of ‘cold’ to ‘hot’ tumors in a syngeneic murine cancer model, creating the ideal clinical setting for immune checkpoint inhibitors.
- In combination with anti-PD-1 antibody, the therapy was able to cure lung and breast cancer bearing mice, resulting in 100% overall survival in mice.
- Induced immune memory response against future implantation of breast cancer cells.
- Technology spun-off from the University of California Davis Cancer Center.
- Effort coupled with the world’s expert in the assessment of the tumor microenvironment.


How does the Nano Immuno-Engager (“NIE”) work in Cancer Immunotherapy?

Transformable Nano Particles (NP)



Self Assembly


NIE-NPs



IV Injection





- 1) NIE delivered to the tumor
- 2) NIE transformed to nanofibrils at the tumor cell membrane
- 3) Nanofibril network at the TME captures T_{eff} cells
- 4) Allows sustained release of an immunostimulant



Our Technology Differentiation: Transformation of Nanoparticles into a Nanofibril Network

Creating a nanofibril network that binds to the cancer cells within the Tumor Micro-Environment that:

- Prolongs the retention of the nanoengager system
- Captures the immune cells
- Activates the immune system
- Spares the normal tissues and organs



Pipeline: Advancing Transformable Peptide Nanoparticle Programs

Product	Indication	Discovery	IND-enabling	Clinical
NIE	NSCLC, Melanoma, Breast, HNSCC			

Leadership

Anthony E. Maida III, PhD

Co-Founder, Chief Executive Officer

Kit S. Lam, MD, PhD

Co-Founder, Chair of Scientific Advisory Board

Robert Pierce, MD

Chief Medical Officer

Patrick Bigot, MBA

Chief Business Officer

Seymour Fine, MD

Head of Regulatory Affairs

Scientific and Clinical Advisors

- Kit S. Lam, MD, PhD (Chair)
- David Gandara, MD • Jose Lutzky, MD
- Jerome Galon, PhD • Kim Margolin, MD
- Primo Lara, MD • James Talmadge, PhD

Board Members

- Anthony E. Maida III PhD (Chair)
- William Ashton • Kit S. Lam, MD, PhD
- Richard Slansky • Bernice Welles, MD



Investor & Company Contact:

BD@T-NanoBio.com